Literature DB >> 3492593

Epidermal growth factor in human cerebrospinal fluid: reduced levels in amyotrophic lateral sclerosis.

D Cieślak, J Szulc-Kuberska, H Stepień, A Klimek.   

Abstract

Epidermal growth factor (EGF), a mitogenic peptide, is widely distributed within the brain and endocrine cells of the gastro-intestinal tract. Using EGF radioreceptor assay, the EGF level was measured in lumbar cerebrospinal fluid from five patients with amyotrophic lateral sclerosis (ALS) and seven patients with intervertebral disc disease as a control group. The patients with ALS showed reduced EGF levels to 662.4 +/- 207 pg/ml as compared with controls 1013 +/- 182.8 pg/ml (P less than 0.02). These results indicate a possible EGF involvement in the pathogenesis of ALS.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3492593     DOI: 10.1007/BF00313927

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  19 in total

1.  Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal.

Authors:  S COHEN
Journal:  J Biol Chem       Date:  1962-05       Impact factor: 5.157

Review 2.  Virological studies of amyotrophic lateral sclerosis: an overview.

Authors:  R T Johnson
Journal:  UCLA Forum Med Sci       Date:  1976

Review 3.  Fibroblast and epidermal growth factors: their uses in vivo and in vitro in studies on cell functions and cell transplantation.

Authors:  D Gospodarowicz
Journal:  Mol Cell Biochem       Date:  1979-05-21       Impact factor: 3.396

4.  Abnormal insulin secretion in amyotrophic lateral sclerosis.

Authors:  F Goto; A Kitamura; A Koto; K Kataoka; H Atsuji
Journal:  J Neurol Sci       Date:  1972-06       Impact factor: 3.181

5.  Abnormal distribution of lead in amyotrophic lateral sclerosis--reestimation of lead in the cerebrospinal fluid.

Authors:  S Conradi; L O Ronnevi; G Nise; O Vesterberg
Journal:  J Neurol Sci       Date:  1980-12       Impact factor: 3.181

6.  Pancreatic dysfunction in patients with amyotrophic lateral sclerosis.

Authors:  D T Quick; M Greer
Journal:  Neurology       Date:  1967-02       Impact factor: 9.910

7.  Human urogastrone and mouse epidermal growth factor share a common receptor site in cultured human fibroblasts.

Authors:  M D Hollenberg; H Gregory
Journal:  Life Sci       Date:  1977-01-15       Impact factor: 5.037

8.  Effect on weakness and spasticity in amyotrophic lateral sclerosis of thyrotropin-releasing hormone.

Authors:  W K Engel; T Siddique; J T Nicoloff
Journal:  Lancet       Date:  1983-07-09       Impact factor: 79.321

9.  Amyotrophic lateral sclerosis: alterations in neurotransmitter receptors.

Authors:  P J Whitehouse; J K Wamsley; M A Zarbin; D L Price; W W Tourtellotte; M J Kuhar
Journal:  Ann Neurol       Date:  1983-07       Impact factor: 10.422

10.  A new hypothesis of the etiology of amyotrophic lateral sclerosis. The DNA hypothesis.

Authors:  W G Bradley; F Krasin
Journal:  Arch Neurol       Date:  1982-11
View more
  4 in total

1.  Effect of bromocriptine and metoclopramide on serum prolactin levels in patients with amyotrophic lateral sclerosis.

Authors:  J Szulc-Kuberska; H Stepień; A Klimek; D Cieślak
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-05       Impact factor: 10.154

2.  Liquid biopsy: a new source of candidate biomarkers in amyotrophic lateral sclerosis.

Authors:  Maite Mendioroz; Leyre Martínez-Merino; Idoia Blanco-Luquin; Amaya Urdánoz; Miren Roldán; Ivonne Jericó
Journal:  Ann Clin Transl Neurol       Date:  2018-04-16       Impact factor: 4.511

3.  EGFR Signaling Termination via Numb Trafficking in Ependymal Progenitors Controls Postnatal Neurogenic Niche Differentiation.

Authors:  Khadar Abdi; Gabriel Neves; Joon Pyun; Emre Kiziltug; Angelica Ahrens; Chay T Kuo
Journal:  Cell Rep       Date:  2019-08-20       Impact factor: 9.423

Review 4.  New Epidermal-Growth-Factor-Related Insights Into the Pathogenesis of Multiple Sclerosis: Is It Also Epistemology?

Authors:  Giuseppe Scalabrino
Journal:  Front Neurol       Date:  2021-11-26       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.